- Clariant expands its Clear Lake, Texas site to add GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients.
- This is Clariant's first U.S. facility producing pharma-grade PEG for oral and topical applications.
- Regional production shortens lead times, improves supply continuity and traceability for pharmaceutical customers across North and Latin America.
Project overview
Clariant is expanding its Clear Lake, Texas site to add GMP-compliant manufacturing of pharmaceutical-grade polyethylene glycol (PEG) excipients; the multi-phase upgrade establishes the company’s first U.S. facility producing pharma-grade PEG for oral and topical applications (press dated March 19, 2026).
Manufacturing and compliance
Facility design and operations target pharmaceutical quality, safety and regulatory expectations, with excipient GMP compliance to provide documentation, traceability and quality assurance; the PEG excipients are registered in relevant pharmacopoeias and have negligible toxicity profiles.
Supply-chain impact
Regional production is intended to shorten lead times, improve supply continuity and predictability for complex production schedules, reduce inventory carrying costs and increase responsiveness for pharmaceutical customers across North and Latin America.
